Evidence map›Paper›PMID 28544233›Full record

ArticleCancer science2017

Overexpression of B-cell lymphoma 6 alters gene expression profile in a myeloma cell line and is associated with decreased DNA damage response.

Kenichi Tahara, Makiko Takizawa, Arito Yamane, Yohei Osaki, Takuma Ishizaki, Takeki Mitsui, Akihiko Yokohama, Takayuki Saitoh, Norifumi Tsukamoto, Morio Matsumoto and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Overexpression ofOncoTargets and therapy · 2022
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Kenichi TaharaDepartment of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan.ORCID http://orcid.org/0000-0003-3652-3287
Makiko TakizawaDepartment of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan.
Arito YamaneDepartment of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan.
Yohei OsakiDepartment of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan.
Takuma IshizakiDepartment of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan.
Takeki MitsuiDepartment of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan.
Akihiko YokohamaDivision of Blood Transfusion Service, Gunma University Hospital, Gunma, Japan.
Takayuki SaitohDepartment of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Gunma, Japan.
Norifumi TsukamotoOncology Center, Gunma University Hospital, Gunma, Japan.
Morio MatsumotoDepartment of Hematology, National Hospital Organization Nishigunma National Hospital, Gunma, Japan.
Hirokazu MurakamiDepartment of Laboratory Sciences, Gunma University Graduate School of Health Sciences, Gunma, Japan.
Yoshihisa NojimaDepartment of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan.
Hiroshi HandaDepartment of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Gunma, Japan.
Gunma University · JPGunma University Hospital · JPNational Hospital Organization · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B-cell lymphoma 6 (BCL6) attenuates DNA damage response (DDR) through gene repression and facilitates tolerance to genomic instability during immunoglobulin affinity maturation in germinal center (GC) B cells. Although BCL6 expression is repressed through normal differentiation of GC B cells into plasma cells, a recent study showed the ectopic expression of BCL6 in primary multiple myeloma (MM) cells. However, the functional roles of BCL6 in MM cells are largely unknown. Here, we report that overexpression of BCL6 in a MM cell line, KMS12PE, induced transcriptional repression of ataxia telangiectasia mutated (ATM), a DDR signaling kinase, which was associated with a reduction in γH2AX formation after DNA damage. In contrast, transcription of known targets of BCL6 in GC B cells was not affected, suggesting a cell type-specific function of BCL6. To further investigate the effects of BCL6 overexpression on the MM cell line, we undertook mRNA sequence analysis and found an upregulation in the genomic mutator activation-induced cytidine deaminase (AID) with alteration in the gene expression profile, which is suggestive of de-differentiation from plasma cells. Moreover, interleukin-6 exposure to KMS12PE led to upregulation of BCL6 and AID, downregulation of ATM, and attenuation of DDR, which were consistent with the effects of BCL6 overexpression in this MM cell line. Taken together, these results indicated that overexpression of BCL6 alters gene expression profile and confers decreased DDR in MM cells. This phenotypic change could be reproduced by interleukin-6 stimulation, suggesting an important role of external stimuli in inducing genomic instability, which is a hallmark of MM cells.

Indexed as

DNA DamageUp-RegulationAICDA (Activation-Induced Cytidine Deaminase)Ataxia Telangiectasia Mutated ProteinsCell Line, TumorCytidine DeaminaseGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksGenomic InstabilityHumansMultiple MyelomaPhenotypeProto-Oncogene Proteins c-bcl-6Sequence Analysis, RNAAICDA (Activation-Induced Cytidine Deaminase)Ataxia Telangiectasia Mutated ProteinsATM protein, humanBCL6 protein, humanCytidine DeaminaseProto-Oncogene Proteins c-bcl-6ATMBCL6DNA repairIL-6multiple myeloma

Identifiers

PMID28544233
PMCPMC5543477
OpenAlexW2694299351

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.